Which is better, ANTHEM.NS or PME.AX?

On the Buffett-Fit framework, Pro Medicus Limited (PME.AX) currently grades higher than ANTHEM.NS — 78/100 (B grade) vs 76/100 (B). That said, "better" depends on which framework you trust — ANTHEM.NS wins on none; PME.AX wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy ANTHEM.NS or PME.AX?

This page is an educational comparison, not investment advice. Both ANTHEM.NS and PME.AX are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is ANTHEM.NS better than PME.AX for value investing?

The two are close on the headline Buffett-Fit score (76/100 vs 78/100), so "better for value investing" depends on which pillar you weight most. The five Buffett pillars + six other frameworks are broken down side-by-side on this page so you can pick the one that fits your style.

What's the difference between ANTHEM.NS and PME.AX on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). ANTHEM.NS currently scores 76/100 (B grade); PME.AX scores 78/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, ANTHEM.NS or PME.AX?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. ANTHEM.NS and PME.AX are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, ANTHEM.NS or PME.AX?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are ANTHEM.NS and PME.AX both Healthcare stocks?

Yes — both ANTHEM BIOSCIENCES LTD (ANTHEM.NS) and Pro Medicus Limited (PME.AX) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this ANTHEM.NS vs PME.AX comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

ANTHEM BIOSCIENCES

ANTHEM.NS$440.61BHealthcare Market cap, Sector

Pro Medicus Limited

PME.AX$16.79BHealthcare Market cap, Sector

Overall winner

Pro Medicus Limited

ANTHEM.NS 07 PME.AX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

ANTHEM.NS0wins

7winsPME.AX

Warren Buffett

76B

B78

Benjamin Graham

89A

A90

Philip Fisher

79B

A98

Peter Lynch

76B

A100

Joel Greenblatt

63C

B84

Charlie Munger

77B

A91

Terry Smith

78B

A96

Side-by-side metrics

Metric	ANTHEM.NS	PME.AX
Market cap	Winner: $440.61B	$16.79B
P/E (TTM)	Winner: 74.0x	147.6x
EV/EBIT	Winner: 52.5x	106.8x
ROIC (TTM)

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

ANTHEM.NS leads on

Market cap$440.61Bvs $16.79B+96%
EV/EBIT52.5xvs 106.8x+51%
P/E (TTM)74.0xvs 147.6x+50%

PME.AX leads on

EPS CAGR 5y37.34%vs 8.24%+78%

More like ANTHEM.NS

ANTHEM.NS vs CAMX.ST ANTHEM.NS vs BSLN.SW ANTHEM.NS vs 1681.HK ANTHEM.NS vs HALO

More like PME.AX

PME.AX vs CAMX.ST

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Industries

Rankings

Glossary

Tools & Methodology

ANTHEM BIOSCIENCES

Pro Medicus Limited

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like ANTHEM.NS

More like PME.AX

Related on invest-like

Key terms in this analysis